Results 21 to 30 of about 10,664 (186)
Antiinflammatory therapy with canakinumab for atherosclerotic disease [PDF]
, 2017 BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.Theunissen E., Li Y., Paulweber B., Fischer S.M., Tzekova M., Wang Y., Chang W.H., Michalaros Y., Ross B., Dong X., Bouvy C., Amerena J., Ligueros M., Manzur F., Roy M., Ibarra J., Grigorova V., Li Z., Manfreda S., Thiessen S., Kostov K., Everett B.M., Veze I., Abrantes J., Raev D., William M., Da Silva D.Jr., Haider K., Li W., Wanderley F.F., Yaoqing H., Lopes R., Baker A., Huynh T., Tamesby G., Yan J., Seung K.B., Yanev T., McPherson C., Buhlman S., Farias E., French J., Li X., Coloma G., Hermans K., Valle M., Unterkircher B., Yakovova S., Brath H., Duda N., Aiub J., Purnell P., Hominal M., Charmarthi B., Gersh B., Mendoza Y., Cuneo C., Bowen L., Saraiva J.F., Julião K., OKeefe D., Luz Serrano H., Gabito A., Todorova A., Caruso G., Yong H., Fernandez A.A., Mehta S., Vincelli G., Maia L., Chouinard G., Lu Z., Mickel C., Zhai Z., Ruschel K., Ghosh N., Diodati J., Vrolix M., Michaud N., Angelova I., Liniado G., Cleveland T., Kobalava Z., Luciardi H., Diaz M., Hwang J.J., Hickey L., Goffinet C., Limaye A.P., Blumenthal R., Cabau J.R., Danik J., Berli M.A., Zadra R., Brady L., O’Neil G., Yang P., Guzman P., Feng Y., Boivin M.C., Hao Y., Cantor W., Fontaine S., Colhoun H., Arora S., Dattani D., Lazov P., MacFadyen J.G., Facello A., Cendali G., Thuren T., Berra F.C., Hasbani E., He Z., Feng Z., Katova T., Koenig W., Moraes J.Jr., Costa Amorim R., Gupta A., Deweerdt N., Mallagray M., Ridker P.M., Plotz M., Dos Santos A., Coronel J., Tawfik R., Abulencia K., Varigos J., Haldane H., Cuentas I., He Y., Saunders K., Roel A., Isaza D., Degennaro N., Marcela Wenetz L.M., Pagnan M., D'Amours D.G., Rodriguez D., Cools F., Tomassi A., Vettus R., Vico M.L., Jose J., Graham J., Vervoort G., Maffei L., Tinnirello V., Manukov D., Kabakchieva V.M., Accini Mendoza JL., Libby P., Reis G., De Wolf L., Glenny J., Jia Z., Scott J., Schultz C., Yang K., Shanahan T., Westberg J.C., Hong T., East C., Jiang T., Chaussé I., Cioffi A., Feitosa G., Zangroniz P., Reis H., Schiavi L.B., Maron B., Pande R., Servaes V., Lamontagne C., Dos Santos F., Dimitrov G., Julien V.E., Hristova K., Lv Y., Chhabra A., Vranckx P., Chou S., Soucy D., Kultursay H., Heeren G., Sinnaeve P., Tahon S., Pramatarova I., Zaidman C., Manolis A.J., Ogawa H., Saini R., Kormann A., Filho P., Liu B., Wu J., Barroso A., Simons N., Fliesser-Goerzer E., Dussan M.A., Jimenez D., Ponce T., Perez Manghi F., Freitas E., Banker K., Anker S.D., Fu G., Genest J., Cheng S., Gospodinov K., Lopez P., Shimokawa H., Mandic L., Alvarisqueta A., Strohner-Kaestenbauer H., Kouz S.M., Lorenzatti A., Hernandez M., Johnston J., Brons S., Sanchez Vallejo G., Ibañez J., Resende I., Araujo Fonseca M., Espinosa V., Kam J., Otasevic P., Bilodeau N., Van Genechten G., Rupka D., Robinson S., Jiang X., Saravia M.A., Zucchetti C., Fonseca F., Ploechl A., Zhang Y., Azize G.M., Maheux K., Xu H., Taverner P., Klemsdal T.O., Sun Z., Han B., Pradhan A., Carabajal T., Mestdagh I., St Amour E., Nicolau J., Bailey K., Yossen M., Abreu M., Rugo H., Soler J., Manyari D., Goudev A., Murphy G., Da Costa F., Cornel J.H., Gotcheva N., Cosgrove S., Sigurdsson A., Chen J., Colquhoun D., Lepage S., Maehara G., Botta C., Seroqui M., Pesce F., Pinheiro L., Aparicio C.V., Jayasinghe R., Polato C., Song M., Jiang J., Xavier J.P., Ord M., Bodanese L., Montana O., Lino E., Barroso W., Garcia Duran R., Lameira A., Avalos V., Vieira N., Vida-Simiti L., Grosse A., Donath M., Deslongchamps F., Wei J., Dos Santos P., Turner F., Gervais B., Rost N., Liu Y., Beaudry M., Olmedo M., Salko T., Hettwer Magedanz E., Fowler V., Wang J., Jure D., Da Silva A., Steringer-Mascherbauer R., Ferraz R., Fonseca A., Garcia F., Nema D., Facello M., Pais P., Salinger M., Milicic D., Da Silva O.Jr., Lainscak M., Vissers C., Ma C., Tan M., Drouin K., Muntaner J., Vezina M., Flores G.S., Manukov I., Lachance P., Zhou H., Nandy P., Singhal A., Rodriguez L.M., Chaverra I., Patino J.M., Bergler-Klein J., De Los Milagros Had M., Vibert J., Bocanera M., Perkins L., Pirenne B., Hartleib M., Lima F., Sang X., Ren L., Echeverria L., Vicente C., Bohula E., Hernandez E., Wei N., Fucci F., Sanchez A., Cuervo A., Petrusheva T., Bolduc H., Hollanders G., Charlier F., De Knijf K., Ferrari V., Ballantyne C., Robbins K., Marchi A.L., Casala J., Franco M., Molina D.I., Roy A., Olenchock B., Mayer T., Lal S., Gralow J., Tisheva-Gospodinova S., Peng L., Richert L., Marinaro S., Budaj A., Abib E.Jr., Lake J., Zalazar L., Forgosh L., Montenegro E., Krum H., Ma G., Belle Isle J., Rassi S., Bourgeois S., Mcintosh C., Yao Z., Romano A., Piskorz D., Venturini C., Vorster M., Mejia I., Garcia Pinna J., Forster T., Pandey S., Burris H., Yuan Z., Prenner A., Ke Y., Otis R., Chen Y., Hilkert R., Woelcke J., Taqueti V., Paz S., Albisu J., Barbosa E., Lauzon C., Liu P., Scaro G., Eccleston D., Makedonska J.J., Affaki G.S., Zhao R., Jirvankar P., Runev N., Barreto M., Glynn R.J., Sarjanovich R., Delforge M., Navarrete S., Liu S., Massaccesi R., Roberts-Thomson P., Levine D., Dellasa M., Grover A., Paganini M., Conrado Y., Urina-Triana M., Vallejo M.A., Budassi N., Roy C., Marengo Garcia De Carvalho L., Manenti E., Martin E., Ouimet F., Duchesne L., Morell Y., Briké C., Barbato E., Felario Junior GA., Cifkova R., Troquay R.P.T., Manning B., Majul C., Savard D., Dellborg M., Bilazarian S., Kastelein J.J.P., Luquez H., Zhang J., Flather M., Pacora F.F., Rossi P.R.F., Manov E., Viola H.G., Moreira L., Manne S., Liu L., Ferreira Dos Santos T., Recoaro R., Qing L., Sirakova-Taseva A., Hiden C., Gosselin G., Weisnagel S.J., Botelho R., Petrov D., Milanova M., Gits F., Dalseg A.M., Commerford P., Martinez J., Ferreira-Jardim A., Perlstein T., Godoy Sanchez M., Jure H., Bata I.R., Pella D., Castillo T., Saporito W., Salvador L., Vertes G., Medina F., Ning M., Silva R., McMahon G., Youssef G., Wu W., Wyss F., Actis M.V., Fucili A., Aiub F., Cotes C., Rodriguez S.M., Collins R., Brodmann M., Genova D., Siostrzonek P., Harris B., Blumberg C., Tan R., Petrauskiene B., Peck C. +499 morecore +5 more sourcesRituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. [PDF]
, 2021 INTRODUCTION
In breastfeeding patients with chronic inflammatory rheumatic diseases, a postpartum flare may require the use of biologics. However, data on the safety of biologics during lactation are scarce, potentially impeding the decision-making ...Förger, Frauke, Eriksson, Klara Kristin, Bosshard, Nicole, Zbinden, Astrid +3 morecore +1 more sourceReasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States
Pediatric Rheumatology Online Journal, 2021 Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood.Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom +9 moredoaj +1 more sourceRilonacept and canakinumab [PDF]
British Journal of Clinical Pharmacology, 2011 Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-Eline A, Dubois, Robert, Rissmann, Adam F, Cohen +2 moreopenaire +2 more sourcesSelective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy
Scientific Reports, 2021 Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated ...Wen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, Chih-Hung Chuang, Yi-An Cheng, I.-Ju Chen, Hui-Ju Liu, Kai-Wen Ho, Tzu-Yi Liao, En-Shuo Liu, Ting-Yi Wu, Long-Sen Chang, Shih-Ting Hong, Tian-Lu Cheng +13 moredoaj +1 more sourceMolecular cancer prevention: Intercepting disease. [PDF]
Mol OncolOncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...Grieco C, Pandya T, Swanton C.europepmc +2 more sourcesCanakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome. [PDF]
, 2023 Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years.Simon Bossart, Bossart, Simon, Kexiang Yan, Laurence Feldmeyer, Luca Borradori, Kristine Heidemeyer, Yawalkar, Nikhil, Seyed Jafari, S Morteza, Yan, Kexiang, Nikhil Yawalkar, S. Morteza Seyed Jafari, Heidemeyer, Kristine, Borradori, Luca, Feldmeyer, Laurence +13 morecore +1 more source
